These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
482 related articles for article (PubMed ID: 19074476)
21. 17beta-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats. Wu CH; Liu JY; Wu JP; Hsieh YH; Liu CJ; Hwang JM; Lee SD; Chen LM; Chang MH; Kuo WW; Shyu JC; Tsai JH; Huang CY Life Sci; 2005 Dec; 78(4):347-56. PubMed ID: 16183079 [TBL] [Abstract][Full Text] [Related]
22. Tanshinone IIA Prevents Leu27IGF-II-Induced Cardiomyocyte Hypertrophy Mediated by Estrogen Receptor and Subsequent Akt Activation. Weng YS; Wang HF; Pai PY; Jong GP; Lai CH; Chung LC; Hsieh DJ; HsuanDay C; Kuo WW; Huang CY Am J Chin Med; 2015; 43(8):1567-91. PubMed ID: 26621443 [TBL] [Abstract][Full Text] [Related]
23. Disruption of actin dynamics regulated by Rho effector mDia1 attenuates pressure overload-induced cardiac hypertrophic responses and exacerbates dysfunction. Abe I; Terabayashi T; Hanada K; Kondo H; Teshima Y; Ishii Y; Miyoshi M; Kira S; Saito S; Tsuchimochi H; Shirai M; Yufu K; Arakane M; Daa T; Thumkeo D; Narumiya S; Takahashi N; Ishizaki T Cardiovasc Res; 2021 Mar; 117(4):1103-1117. PubMed ID: 32647865 [TBL] [Abstract][Full Text] [Related]
25. BMP-7 attenuates left ventricular remodelling under pressure overload and facilitates reverse remodelling and functional recovery. Merino D; Villar AV; García R; Tramullas M; Ruiz L; Ribas C; Cabezudo S; Nistal JF; Hurlé MA Cardiovasc Res; 2016 Jun; 110(3):331-45. PubMed ID: 27068510 [TBL] [Abstract][Full Text] [Related]
26. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Liu Q; Chen Y; Auger-Messier M; Molkentin JD Circ Res; 2012 Apr; 110(8):1077-86. PubMed ID: 22403241 [TBL] [Abstract][Full Text] [Related]
27. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice. Chiang CS; Huang CH; Chieng H; Chang YT; Chang D; Chen JJ; Chen YC; Chen YH; Shin HS; Campbell KP; Chen CC Circ Res; 2009 Feb; 104(4):522-30. PubMed ID: 19122177 [TBL] [Abstract][Full Text] [Related]
28. Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. Pedram A; Razandi M; Aitkenhead M; Levin ER J Biol Chem; 2005 Jul; 280(28):26339-48. PubMed ID: 15899894 [TBL] [Abstract][Full Text] [Related]
29. Peroxiredoxin-1 ameliorates pressure overload-induced cardiac hypertrophy and fibrosis. Tang C; Yin G; Huang C; Wang H; Gao J; Luo J; Zhang Z; Wang J; Hong J; Chai X Biomed Pharmacother; 2020 Sep; 129():110357. PubMed ID: 32531679 [TBL] [Abstract][Full Text] [Related]
30. The valosin-containing protein is a novel repressor of cardiomyocyte hypertrophy induced by pressure overload. Zhou N; Ma B; Stoll S; Hays TT; Qiu H Aging Cell; 2017 Oct; 16(5):1168-1179. PubMed ID: 28799247 [TBL] [Abstract][Full Text] [Related]
32. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Facundo HT; Brainard RE; Watson LJ; Ngoh GA; Hamid T; Prabhu SD; Jones SP Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H2122-30. PubMed ID: 22408028 [TBL] [Abstract][Full Text] [Related]
33. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females. Voloshenyuk TG; Gardner JD Am J Physiol Regul Integr Comp Physiol; 2010 Aug; 299(2):R683-93. PubMed ID: 20504902 [TBL] [Abstract][Full Text] [Related]
34. Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy. Zou Y; Liang Y; Gong H; Zhou N; Ma H; Guan A; Sun A; Wang P; Niu Y; Jiang H; Takano H; Toko H; Yao A; Takeshima H; Akazawa H; Shiojima I; Wang Y; Komuro I; Ge J Hypertension; 2011 Dec; 58(6):1099-110. PubMed ID: 21986507 [TBL] [Abstract][Full Text] [Related]
35. AAV-mediated expression of NFAT decoy oligonucleotides protects from cardiac hypertrophy and heart failure. Remes A; Wagner AH; Schmiedel N; Heckmann M; Ruf T; Ding L; Jungmann A; Senger F; Katus HA; Ullrich ND; Frey N; Hecker M; Müller OJ Basic Res Cardiol; 2021 Jun; 116(1):38. PubMed ID: 34089101 [TBL] [Abstract][Full Text] [Related]
36. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy. Luo Y; Jiang N; May HI; Luo X; Ferdous A; Schiattarella GG; Chen G; Li Q; Li C; Rothermel BA; Jiang D; Lavandero S; Gillette TG; Hill JA Circulation; 2021 Jul; 144(1):34-51. PubMed ID: 33821668 [TBL] [Abstract][Full Text] [Related]
38. Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin. Lin H; Li Y; Zhu H; Wang Q; Chen Z; Chen L; Zhu Y; Zheng C; Wang Y; Liao W; Bin J; Kitakaze M; Liao Y Cardiovasc Res; 2020 Jan; 116(1):101-113. PubMed ID: 30689763 [TBL] [Abstract][Full Text] [Related]
39. RyR2 Stabilizer Attenuates Cardiac Hypertrophy by Downregulating TNF-α/NF-κB/NLRP3 Signaling Pathway through Inhibiting Calcineurin. Gao Y; Li S; Liu X; Si D; Chen W; Yang F; Sun H; Yang P J Cardiovasc Transl Res; 2024 Jun; 17(3):481-495. PubMed ID: 38652413 [TBL] [Abstract][Full Text] [Related]
40. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Tang M; Li J; Huang W; Su H; Liang Q; Tian Z; Horak KM; Molkentin JD; Wang X Cardiovasc Res; 2010 Dec; 88(3):424-33. PubMed ID: 20601385 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]